Imetelstat

Arriello Announces Signing of First US Company to Use IntelliCASE for Clinical Pharmacovigilance Reporting

Retrieved on: 
Tuesday, January 26, 2021
Health, Pharmaceuticals policy, Clinical research, Drug Safety, Health care quality, Imetelstat, Pharmacovigilance, Telomerase, Drug Safety, BioPharm

Geron a late-stage clinical biopharmaceutical company headquartered in California, is focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Key Points: 
  • Geron a late-stage clinical biopharmaceutical company headquartered in California, is focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
  • Arriello's IntelliCASE app supports the capture of adverse event data via mobile devices, ensuring that detailed pharmacovigilance information is captured promptly and correctly.
  • With this powerful, targeted app, Arriello offers an easy to use pharmacovigilance system that's proved readily adaptable."
  • These services include market consultancy, global regulatory affairs strategy and implementation, full and local pharmacovigilance solutions, clinical drug safety and quality and compliance auditing systems.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, January 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Financial markets, Finance, Branches of biology, Stem cells, Corporate finance, Geron Corporation, Stock market, Imetelstat, Telomerase, NASDAQ, Stock, Geron

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on January 20, 2021 at an exercise price of $1.74 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The options were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

Retrieved on: 
Thursday, January 14, 2021
Oncology, Health, Hospitals, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biotechnology, Life sciences, Stem cells, Geron Corporation, Imetelstat, Telomerase, Geron

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m.
  • A live audio webcast of the presentation will be available on Gerons website, www.geron.com/investors/events .
  • A replay of the webcast will be available on the Companys website for 30 days.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis

Retrieved on: 
Friday, December 11, 2020
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Clinical medicine, Geron Corporation, Imetelstat, Life sciences, Janus kinase inhibitor, Biotechnology, Primary myelofibrosis, Myelodysplastic syndrome, Myelofibrosis (MF), Imetelstat, Geron

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
  • As Gerons second registration-enabling Phase 3 trial in hematologic myeloid malignancies, the IMpactMF trial represents a milestone for our Company, said Aleksandra Rizo, M.D., Ph.D., Gerons Chief Medical Officer.
  • Patients eligible for the trial will be required to be non-responsive, or refractory, to treatment with a JAK inhibitor.
  • Geron is currently conducting two registration-enabling Phase 3 clinical trials of imetelstat: IMerge, a Phase 2/3 trial in lower risk myelodysplastic syndromes (MDS), and IMpactMF, a Phase 3 trial in refractory myelofibrosis (MF).

Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS

Retrieved on: 
Thursday, December 10, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Life sciences, Health sciences, Health, Geron Corporation, Imetelstat, Myelodysplastic syndrome, Clinical trial, Myelodysplastic Syndromes (MDS), Imetelstat, Geron

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS).
  • Data from the IMerge Phase 2 were recently presented at the American Society of Hematology Annual Meeting and support the ongoing Phase 3.
  • The IMerge Phase 3 is a double-blind, randomized, placebo-controlled clinical trial with registration intent.
  • Current clinical studies of imetelstat include IMerge, an ongoing Phase 2/3 trial in lower risk myelodysplastic syndromes (MDS), and IMpactMF, an upcoming Phase 3 clinical trial in refractory myelofibrosis (MF).

Geron Reports Ten Imetelstat Presentations at American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 7, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Biology, Biotechnology, Imetelstat, Stem cells, Geron Corporation, Telomerase, American Society of Hematology, European Hematology Association, Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Biology, Biotechnology, Imetelstat, Stem cells, Geron Corporation, Telomerase, American Society of Hematology, European Hematology Association, Phase 2 IMerge and IMbark Trials, Imetelstat, Geron

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Companys first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Companys first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting.
  • These biomarker data together with the durability of transfusion independence provide evidence for the disease-modifying activity of imetelstat.
  • These data were previously presented at the European Hematology Association (EHA) Annual Congress in June.
  • This oral presentation reported significant dose-dependent reduction of mutation burden by imetelstat, including complete elimination of mutations in MF driver and non-driver genes.

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, November 19, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Biotechnology, Biology, Stem cells, Corporate finance, Geron Corporation, Stock market, Imetelstat, Telomerase, Geron, Stock, Option

Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
  • The stock option was granted on November 18, 2020 at an exercise price of $1.90 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The option was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of a stock option agreement covering the grant and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Geron to Present at the Stifel Virtual Healthcare Conference

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Biotechnology, Life sciences, Stem cells, Geron Corporation, Imetelstat, Telomerase, Geron

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m.
  • A live audio webcast of the presentation will be available on Gerons website, www.geron.com/investors/events .
  • If you are unable to listen to the live presentation, an archived webcast will be available on the Companys website for 30 days.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Geron Announces Ten Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting

Retrieved on: 
Wednesday, November 4, 2020
Health, Genetics, Clinical trials, General Health, Pharmaceutical, Biotechnology, Imetelstat, European Hematology Association, EHA, Medicine, Health care, Imetelstat, Geron

These data were previously presented at the European Hematology Association (EHA) Annual Congress in June.

Key Points: 
  • These data were previously presented at the European Hematology Association (EHA) Annual Congress in June.
  • Results from new analyses on samples from patients in the IMbark Phase 2 clinical trial highlight significant dose-dependent reductions of mutation burden by imetelstat.
  • In accordance with ASH policies, abstracts submitted to the ASH Annual Meeting are embargoed from the time of submission.
  • The slide presentation and posters will be available at www.geron.com/r-d/publications following the ASH Annual Meeting presentations.

Geron to Announce Third Quarter Financial Results on November 5, 2020

Retrieved on: 
Thursday, October 29, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Biotechnology, Biology, Stem cells, Geron Corporation, Imetelstat, Telomerase, Geron, Lluís Companys

Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Companys website at www.geron.com/investors .

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Companys website at www.geron.com/investors .
  • Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m.
  • If you are unable to listen to the live call, an archived webcast will be available on the Companys website for 30 days.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.